Literature DB >> 25763727

Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events.

Jennifer J Kwak1, Sree Harsha Tirumani, Annick D Van den Abbeele, Phillip J Koo, Heather A Jacene.   

Abstract

Cancer immunotherapy is changing the imaging evaluation of cancer treatment response and treatment-related toxic effects. New emerging patterns of treatment response and treatment-related toxic effects after treatment with immunomodulating agents have been observed. Treatment response after immunomodulatory therapy can be associated with significantly delayed decrease in tumor size, and new or enlarging tumors observed soon after completion of treatment may not reflect disease progression. In addition, activation of the immune system to fight cancer may lead to unwanted autoimmune-mediated toxic effects that could be mistaken for metastatic disease or misdiagnosed as a non-treatment-related process and delay appropriate clinical management. Radiologists must recognize the novel treatment response patterns and the wide range of autoimmune toxic effects, which should not be mistaken for treatment failure or metastatic disease progression. (©)RSNA, 2015.

Entities:  

Mesh:

Year:  2015        PMID: 25763727     DOI: 10.1148/rg.352140121

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  44 in total

1.  Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma.

Authors:  Ivetta Danylesko; Roni Shouval; Noga Shem-Tov; Ronit Yerushalmi; Elad Jacoby; Michal J Besser; Avichai Shimoni; Tima Davidson; Katia Beider; Dror Mevorach; Shalev Fried; Arnon Nagler; Abraham Avigdor
Journal:  Bone Marrow Transplant       Date:  2020-12-03       Impact factor: 5.483

Review 2.  The value of 18F-FDG PET/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis.

Authors:  Narjess Ayati; Ramin Sadeghi; Zahra Kiamanesh; Sze Ting Lee; S Rasoul Zakavi; Andrew M Scott
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-07-29       Impact factor: 9.236

Review 3.  [Adverse effects of immunotherapy : Clinical aspects, radiological and nuclear medicine results].

Authors:  G Widmann; V A Nguyen; J Plaickner; W Jaschke
Journal:  Radiologe       Date:  2017-10       Impact factor: 0.635

Review 4.  [Influence of immunomodulators on urological imaging].

Authors:  F Peisen; W Thaiss; N Tietze; S Rausch; B Amend; K Nikolaou; J Bedke; A Stenzl; S Kaufmann
Journal:  Urologe A       Date:  2019-12       Impact factor: 0.639

Review 5.  Immune-related tumour response assessment criteria: a comprehensive review.

Authors:  Bhanusupriya Somarouthu; Susanna I Lee; Trinity Urban; Cheryl A Sadow; Gordon J Harris; Avinash Kambadakone
Journal:  Br J Radiol       Date:  2018-02-14       Impact factor: 3.039

6.  FLT-PET At 6 Weeks Predicts Response Assessed by CT at 12 Weeks in Melanoma Patients Treated With Pembrolizumab.

Authors:  Randy Yeh; Megan H Trager; Emanuelle M Rizk; Grace G Finkel; Luke W Barker; Richard D Carvajal; Larisa J Geskin; Gary K Schwartz; Lawrence Schwartz; Laurent Dercle; Yvonne M Saenger
Journal:  Clin Nucl Med       Date:  2020-04       Impact factor: 7.794

Review 7.  Abdominal CT manifestations of adverse events to immunotherapy: a primer for radiologists.

Authors:  Ali Pourvaziri; Anushri Parakh; Pierpaolo Biondetti; Dushyant Sahani; Avinash Kambadakone
Journal:  Abdom Radiol (NY)       Date:  2020-09

8.  Immune Modulation Therapy and Imaging: Workshop Report.

Authors:  Anthony F Shields; Paula M Jacobs; Mario Sznol; Michael M Graham; Ron N Germain; Lawrence G Lum; Elizabeth M Jaffee; Elisabeth G E de Vries; Sridhar Nimmagadda; Annick D Van den Abbeele; David K Leung; Anna M Wu; Elad Sharon; Lalitha K Shankar
Journal:  J Nucl Med       Date:  2017-08-17       Impact factor: 10.057

Review 9.  Managing Metastatic Castration-Resistant Prostate Cancer in the Pre-chemotherapy Setting: A Changing Approach in the Era of New Targeted Agents.

Authors:  Zafeiris Zafeiriou; Anuradha Jayaram; Adam Sharp; Johann S de Bono
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

10.  Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors.

Authors:  Joseph Song; Priyanka Kadaba; Amanda Kravitz; Adilia Hormigo; Joshua Friedman; Puneet Belani; Constantinos Hadjipanayis; Benjamin M Ellingson; Kambiz Nael
Journal:  Neuro Oncol       Date:  2020-11-26       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.